Free Trial
NASDAQ:VALN

Valneva (VALN) Stock Price, News & Analysis

Valneva logo
$5.75
+0.10 (+1.77%)
(As of 11/1/2024 ET)

About Valneva Stock (NASDAQ:VALN)

Key Stats

Today's Range
$5.74
$5.83
50-Day Range
$5.55
$7.98
52-Week Range
$5.40
$14.49
Volume
33,271 shs
Average Volume
16,346 shs
Market Capitalization
$467.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.50
Consensus Rating
Buy

Company Overview

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Valneva Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
31st Percentile Overall Score

VALN MarketRank™: 

Valneva scored higher than 31% of companies evaluated by MarketBeat, and ranked 821st out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Valneva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Valneva has only been the subject of 1 research reports in the past 90 days.

  • Read more about Valneva's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Valneva is -11.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Valneva is -11.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Valneva has a P/B Ratio of 2.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Valneva's valuation and earnings.
  • Percentage of Shares Shorted

    0.07% of the float of Valneva has been sold short.
  • Short Interest Ratio / Days to Cover

    Valneva has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Valneva has recently increased by 10.40%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Valneva does not currently pay a dividend.

  • Dividend Growth

    Valneva does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.07% of the float of Valneva has been sold short.
  • Short Interest Ratio / Days to Cover

    Valneva has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in Valneva has recently increased by 10.40%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    1 people have searched for VALN on MarketBeat in the last 30 days.
  • MarketBeat Follows

    4 people have added Valneva to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Valneva insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.91% of the stock of Valneva is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 11.39% of the stock of Valneva is held by institutions.

  • Read more about Valneva's insider trading history.
Receive VALN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter.

VALN Stock News Headlines

Valneva’s Chikungunya Vaccine Gains Scientific Spotlight
Sell NVDA Now?
Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.
Buy Rating for VALN: Strong Vaccine Pipeline and Financial Upside
High Growth Tech Stocks In France October 2024
See More Headlines

VALN Stock Analysis - Frequently Asked Questions

Valneva's stock was trading at $10.37 at the beginning of 2024. Since then, VALN stock has decreased by 44.6% and is now trading at $5.75.
View the best growth stocks for 2024 here
.

Valneva SE (NASDAQ:VALN) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.02. The business earned $40.97 million during the quarter, compared to analyst estimates of $46.83 million. Valneva had a negative net margin of 21.31% and a negative trailing twelve-month return on equity of 20.01%.

Valneva (VALN) raised $99 million in an initial public offering (IPO) on Thursday, May 6th 2021. The company issued 3,500,000 shares at a price of $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. acted as the underwriters for the IPO.

Top institutional shareholders of Valneva include AlphaCentric Advisors LLC (0.15%).

Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Valneva investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/13/2024
Today
11/02/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VALN
Fax
N/A
Employees
700
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.50
High Stock Price Target
$20.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+221.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-109,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$165.52 million
Book Value
$2.00 per share

Miscellaneous

Free Float
69,133,000
Market Cap
$467.19 million
Optionable
Not Optionable
Beta
2.17
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:VALN) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners